Last reviewed · How we verify
Hemospan (MP4OX)
Hemospan is a pegylated hemoglobin-based oxygen carrier that binds and transports oxygen to tissues, functioning as a blood substitute or oxygen therapeutic.
Hemospan is a pegylated hemoglobin-based oxygen carrier that binds and transports oxygen to tissues, functioning as a blood substitute or oxygen therapeutic. Used for Acute blood loss / hemorrhagic shock requiring oxygen therapeutic support, Severe anemia in perioperative or trauma settings.
At a glance
| Generic name | Hemospan (MP4OX) |
|---|---|
| Also known as | MP4OX solution, 4.3 g/dL MalPEG-Hb, PEGylated Hb, 4.3 g/dL MalPEG Hb |
| Sponsor | Sangart |
| Drug class | Hemoglobin-based oxygen carrier |
| Target | Hemoglobin (oxygen binding and transport) |
| Modality | Small molecule |
| Therapeutic area | Hematology / Critical Care / Trauma |
| Phase | Phase 3 |
Mechanism of action
MP4OX is a modified hemoglobin molecule conjugated with polyethylene glycol (PEG) to extend its half-life and reduce immunogenicity. It carries and delivers oxygen to tissues similarly to red blood cells, making it useful in situations of acute blood loss or severe anemia where oxygen delivery is compromised. The pegylation allows it to remain in circulation longer than unmodified hemoglobin while minimizing adverse immune and renal effects.
Approved indications
- Acute blood loss / hemorrhagic shock requiring oxygen therapeutic support
- Severe anemia in perioperative or trauma settings
Common side effects
- Hypertension
- Abdominal pain
- Back pain
- Elevated liver enzymes
Key clinical trials
- Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty (PHASE3)
- Safety Study of Hemospan® in Prostatectomy Patients (PHASE2)
- Increasing Dose Safety Study of Hemospan in Orthopedic Surgery Patients (PHASE1, PHASE2)
- Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty (PHASE3)
- Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |